Eliglustat + Mao Inhibitors Interaction
Contraindicatedinteraction on record
Description
Strong CYP3A inhibitors are contraindicated in intermediate and poor CYP2D6 metabolizers due to increased eliglustat concentrations and cardiac arrhythmia risk.
Mechanism
Inhibition of CYP3A metabolism of eliglustat
Source: NLP:eliglustat